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Earlier removal of the aortic cannula may have prevented 
thiS complication. 
Thrombus formation, both microscopic and macroscopic, 
has the potential for disastrous complications in patients 
receMng antifibrinolytic therapy. The risk of thrombus for- 
mation may be increased with stasis of blood. We would 
therefore recommend early removal of intravascular cathe- 
ters when antifibrinolytic therapy has been instituted. 
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RECURRENT THROMBOSIS OF BIVENTRICULAR-SUPPORT DEVICES ASSOCIATED WITH 
ACCELERATED INTRAVASCULAR COAGULATION AND INCREASED HEPARIN REQUIREMENTS 
George J. Despotis, MD, Vladimir Levine, MD, Alexander Alsoufiev, MD, Heinrich Joist, MD, PhD, 
Lawrence T. Goodnough, MD, and Michael Pasque, MD, St. Louis, Mo. 
Thrombus formation in ventricular-assist devices has 
occurred espite apparently adequate anticoagulant ther- 
apy. The factors and mechanisms involved in the devel- 
opment of this potentially serious complication are poorly 
understood. We describe the case of a patient in whom 
multiple episodes of thrombosis developed in biventricu- 
lar-support devices (BIVADs) used as a bridge to cardiac 
transplantation. These episodes were associated with accel- 
erated intravascular coagulation and increased heparin re- 
quirements, which seemed to be favorably affected by ad- 
ministration of fresh-frozen plasma (FFP). 
A 44-year-old white man came to our tertiary care 
institution for cardiac transplantation evaluation after a 
recent episode of congestive heart failure that was unrespon- 
sive to aggressive medical management. After an 8-year 
history of myocardial infarctions and progressive heart fail- 
ure, he began a period of rapid deterioration 4 months 
before admission, at which time evaluation revealed end- 
stage ischemic cardiomyopathy. Cardiac catheterization 
demonstrated global left ventricular hypokinesia with an 
ejection fraction of 7% and severe coronary artery dis- 
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ease; transthoracic e hocardiography revealed moderately 
severe mitral and moderate tricuspid regurgitation. Previ- 
ous management of his cardiac ondition included inotro- 
pic support, afterload reduction, and diuresis. Laboratory 
evaluation showed elevated transaminase l vels, reduced 
total protein level, reduced albumin level, and increased 
bilirubin level and prothrombin time, consistent with 
chronic, passive liver congestion. 
On arrival, the patient was noted to be in severe 
congestive heart failure accompanied by tachycardia t 
150 beats/rain as a result of atrial flutter with a 2:1 
conduction block. Initial treatment consisted of cardiover- 
sion to sinus rhythm followed by intravenous administra- 
tion of nipride, dobutamine, and amrinone and subcuta- 
neous injection of heparin (5000 U every 12 hours). The 
patient's condition worsened uring the next several days, 
with development of cardiogenic shock (systolic blood 
pressure, 70 to 80 mm Hg; pulmonary artery wedge 
pressure, 38 mm Hg; cardiac index <1.5) despite large doses 
of dobutamine and amrinone necessitating bypass resus- 
citation on day 9 (Fig. 1). Subsequently, ABIOMED 
(ABIOMED Cardiovascular, Inc., Danvers, MasS.) biven- 
tricular support devices (BIVADs) were inserted as a 
bridge t ° transplantation. After insertion of the BIVADs, 
the patient had anticoagulation with a continuous infusion 
of heparin at 1800 to 2100 U/hr to maintain the celite 
activated clotting time (ACT) between 180 and 200 sec- 
onds. During days 9 through 19, a progressive increase in 
heparin requirements (4000 U/hr) was noted. On day 19, 
clot formation in the BIVAD circuit necessitated emer- 
gency operative replacement of the BIVAD system (Fig. 
1). Recurrent BIVAD thrombosis was noted on day 20, 
necessitating a second replacement of the BIVAD system. 
In light of these events and a decrease in the platelet 
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Fig. 1.. Alteration in hemostatic system and heparin dose requirements in relationship to the clinical 
course of a patient with BIVADs inserted for heart failure caused by end-stage ischemic ardiomyopathy. 
Ordinate: prothrombin time (PT) in seconds, average celite ACT in seconds, and average rate of heparin 
infusion in U/hr/10 (Hep. dose), activated partial thromboplastin time (APTT) in seconds, and platelet 
count in 103 cells/txl (Platelets). 
count after operation from 230,000 to 68,000 ceils/txl 
(days 20 through 24), heparin-induced thrombocytopenia- 
thrombosis was suspected and a change in heparin from 
porcine to bovine was made on day 24. Heparin-induced 
thrombocytopenia-thrombosis was ubsequently ruled out 
by negative results of a platelet serotonin release study. 
The BIVAD system was replaced for a third time on day 
34 after visualization of clots in the circuit; this was also 
associated with an appreciable increase in heparin re- 
quirements. The persistently high heparin requirements 
(4000 U/hr) prompted administration of 2 U FFP on day 
43. The FFP was associated with a 50% decrease in 
heparin dose requirements (Fig. 1), In view of this finding, 
informed consent was obtained and blood specimens were 
collected daily for a more detailed evaluation of the 
patient's coagulation status, including response to heparin 
as estimated with a heparin dose-ACT response slope 
(HDR slope ) obtained by means of an automated bedside 
assay (HDR assay; Medtronic Hemo Tec, Parker, Colo.), 
and levels of antithrombin III, factor V, factor X, tissue 
factor pathway inhibitor, platelet counts, anti-factOr Xa 
heparin concentration, protein C, protein S, fibrinopep-' 
tide A, and prothrombin fragment 1.2. Factor X and 
protein C and S concentrations were normal during this 
period. The results of the other assays obtained during 
days 44 through 57 are summarized in Fig. 2. Heparin 
requirements again progressively increased uring days 44 
through 48, at which time the patient underwent cardiac 
transplantation. The patient had an unventful postopera- 
tive course and was discharged without neurologic deficits. 
It is well established that extracorporeal circulation carl 
induce complex hemostatic system abnormalities, in part 
mediated by activation of platelets, coagulation, and fibrino- 
lysis with consumption of platelets and labile coagulation 
factors and sometimes associated with thrombosis. Heparin 
anticoagulation protocols are frequently used to pre- 
vent excessive hemostatic system activation and throm- 
bosis. Heparin anticoagulation is routinely monitored 
with the ACT, values of which are maintained at 
approximately 200 seconds to minimize bleeding, a 
frequent complication of extracorporeal life support. 1
Numerous variables can affect ACT measurements, 2 
h0wever, and therapeutic ACT values do not guarantee 
suppression of excessive thrombin generation during 
extracorporeal circulation. 3 Our evaluation indicates 
that the multiple thrombotic episodes in this patient 
may have been related to an underlying state of exces- 
sive hemostatic system activation, due at least in part to 
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Fig, 2. Hematologic measurements during hospitalization days 44 through 57 after infusion of 2 U FFP for 
heparin resistance. Left ordinate: anti-factor Xa heparin concentration i  U/ml (anti-Xa), fibrinopeptide A 
in ng/ml/10 (FPA), prothrombin fragment 1.2 in mmol/L/10 (F1.2), antithrombin Ill in U/ml (ATIII), and 
factor V in U/m (FV). Right ordinate: average rate of heparin infusion in U/hr/10 (Hep. dose). HDR slope 
in sec/U/ml, and platelet count in 103 cells//xl (Platelets). 
inadequate anticoagulation asdemonstrated by a dose- 
time association between increased heparin require- 
ments and thrombotic events, (2) rapidly and markedly 
reduced heparin requirements after infusion of even 
relatively small amounts of FFP, and (3) progressive 
rises in prothrombin fragment 1.2 level, fibrinopeptide 
A level, and heparin requirements in conjunction with a 
fall in HDR slope and antithrombin III and factor V 
levels during days 44 through 48. Increased heparin 
resistance as a result of reduced antithrombin III, 
previously described in cardiac surgical patients receiv- 
ing heparin before operation, 4 thus may result in pro- 
gressive consumption coagulopathy even when ACT 
values are within the therapeutic range. Furthermore, 
patients with cardiomyopathy who require biventricular 
support have been noted to be at particularly high risk 
for thrombosis as a result of hypercoagulability. 5 Fur- 
ther prospective studies are needed to determine more 
accurately the prevalence of abnormal bleeding and 
thrombosis with BIVADs, to determine the optimal thera- 
peutic range for heparin and coumadin anticoagulation with 
BIVADS by means of appropriate point-of-care tests now 
available, Such as HDR slope and heparin concentration, as
well as sensitive markers for excessive coagulation and 
fibrinolysis activation that allow more accurate assessment of
the coagulation system and identification of patients at risk, 
and to evaluate alternate forms of antithrombofic therapy 
such as reversible, specific inhibition of thrombin and plate- 
lets or heparin-bound extracorporeal circuits. 
REFERENCES 
1. Bartlett RH. Extracorporeal life support for cardiopulmonary 
failure. Curr Probl Surg 1990;27:621-705. 
2. Despotis GJ, Summerfield AL, Joist JH, et aI. Comparison of 
activated coagulation time and whole blood heparin measure- 
ments to laboratory plasma nti-Xa heparin concentration i
cardiac surgical patients. J Thorac Cardiovasc Surg 1994;108: 
1076-82. 
3. Slaughter TF, Lebleu TH, Douglas JM, et al. Characterization 
of prothrombin activation during cardiac surgery by hemo- 
static molecular markers. Anesthesiology 1994;80:520-6. 
4. Esposito RA, Culliford AT, Colvin SB, Thomas S J, Lackner 
H, Spencer FC. Heparin resistance during cardiopulmonary 
bypass: the role of heparin pretreatment. J Thorac Cardiovasc 
Surg 1983;85:346-53. 
5. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama 
T, Shimada K. The coagulation system is activated in idio- 
pathic cardiomyopathy. J Am Coll Cardiol 1995;25:1634-40. 
